Cargando…

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

PURPOSE: Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Wei, Shi, Ming, Yang, Jingjing, Cao, Jiang, Xu, Linyan, Yan, Dongmei, Yao, Meixue, Liu, Hui, Li, Weidong, Zhang, Bing, Sun, Kemeng, Song, Xuguang, Sun, Cai, Jiao, Jun, Qin, Yuanyuan, Sang, Tingting, Ma, Yuanyuan, Wu, Mei, Gao, Xiang, Cheng, Hai, Yan, Zhiling, Li, Depeng, Sun, Haiying, Zhu, Feng, Wang, Ying, Zeng, Lingyu, Li, Zhenyu, Zheng, Junnian, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433814/
https://www.ncbi.nlm.nih.gov/pubmed/32608579
http://dx.doi.org/10.1002/cam4.3259
_version_ 1783572026269630464
author Sang, Wei
Shi, Ming
Yang, Jingjing
Cao, Jiang
Xu, Linyan
Yan, Dongmei
Yao, Meixue
Liu, Hui
Li, Weidong
Zhang, Bing
Sun, Kemeng
Song, Xuguang
Sun, Cai
Jiao, Jun
Qin, Yuanyuan
Sang, Tingting
Ma, Yuanyuan
Wu, Mei
Gao, Xiang
Cheng, Hai
Yan, Zhiling
Li, Depeng
Sun, Haiying
Zhu, Feng
Wang, Ying
Zeng, Lingyu
Li, Zhenyu
Zheng, Junnian
Xu, Kailin
author_facet Sang, Wei
Shi, Ming
Yang, Jingjing
Cao, Jiang
Xu, Linyan
Yan, Dongmei
Yao, Meixue
Liu, Hui
Li, Weidong
Zhang, Bing
Sun, Kemeng
Song, Xuguang
Sun, Cai
Jiao, Jun
Qin, Yuanyuan
Sang, Tingting
Ma, Yuanyuan
Wu, Mei
Gao, Xiang
Cheng, Hai
Yan, Zhiling
Li, Depeng
Sun, Haiying
Zhu, Feng
Wang, Ying
Zeng, Lingyu
Li, Zhenyu
Zheng, Junnian
Xu, Kailin
author_sort Sang, Wei
collection PubMed
description PURPOSE: Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. METHODS: Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti‐CD19 and anti‐CD20 CAR‐T cells. Treatment response, toxicity, and persistence were monitored continuously. RESULTS: Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%‐94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%‐74.3%) had a complete response (CR). Peak levels of anti‐CD19 and anti‐CD20 CAR cells were associated with response (P = .007 and .002). Grade 3‐4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression‐free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. CONCLUSIONS: Coadministration of anti‐CD19 and CD20 CAR‐T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178.
format Online
Article
Text
id pubmed-7433814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74338142020-08-20 Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma Sang, Wei Shi, Ming Yang, Jingjing Cao, Jiang Xu, Linyan Yan, Dongmei Yao, Meixue Liu, Hui Li, Weidong Zhang, Bing Sun, Kemeng Song, Xuguang Sun, Cai Jiao, Jun Qin, Yuanyuan Sang, Tingting Ma, Yuanyuan Wu, Mei Gao, Xiang Cheng, Hai Yan, Zhiling Li, Depeng Sun, Haiying Zhu, Feng Wang, Ying Zeng, Lingyu Li, Zhenyu Zheng, Junnian Xu, Kailin Cancer Med Clinical Cancer Research PURPOSE: Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. METHODS: Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti‐CD19 and anti‐CD20 CAR‐T cells. Treatment response, toxicity, and persistence were monitored continuously. RESULTS: Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%‐94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%‐74.3%) had a complete response (CR). Peak levels of anti‐CD19 and anti‐CD20 CAR cells were associated with response (P = .007 and .002). Grade 3‐4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression‐free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. CONCLUSIONS: Coadministration of anti‐CD19 and CD20 CAR‐T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178. John Wiley and Sons Inc. 2020-07-01 /pmc/articles/PMC7433814/ /pubmed/32608579 http://dx.doi.org/10.1002/cam4.3259 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Sang, Wei
Shi, Ming
Yang, Jingjing
Cao, Jiang
Xu, Linyan
Yan, Dongmei
Yao, Meixue
Liu, Hui
Li, Weidong
Zhang, Bing
Sun, Kemeng
Song, Xuguang
Sun, Cai
Jiao, Jun
Qin, Yuanyuan
Sang, Tingting
Ma, Yuanyuan
Wu, Mei
Gao, Xiang
Cheng, Hai
Yan, Zhiling
Li, Depeng
Sun, Haiying
Zhu, Feng
Wang, Ying
Zeng, Lingyu
Li, Zhenyu
Zheng, Junnian
Xu, Kailin
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title_full Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title_fullStr Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title_full_unstemmed Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title_short Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
title_sort phase ii trial of co‐administration of cd19‐ and cd20‐targeted chimeric antigen receptor t cells for relapsed and refractory diffuse large b cell lymphoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433814/
https://www.ncbi.nlm.nih.gov/pubmed/32608579
http://dx.doi.org/10.1002/cam4.3259
work_keys_str_mv AT sangwei phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT shiming phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT yangjingjing phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT caojiang phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT xulinyan phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT yandongmei phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT yaomeixue phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT liuhui phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT liweidong phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT zhangbing phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT sunkemeng phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT songxuguang phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT suncai phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT jiaojun phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT qinyuanyuan phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT sangtingting phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT mayuanyuan phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT wumei phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT gaoxiang phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT chenghai phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT yanzhiling phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT lidepeng phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT sunhaiying phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT zhufeng phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT wangying phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT zenglingyu phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT lizhenyu phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT zhengjunnian phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma
AT xukailin phaseiitrialofcoadministrationofcd19andcd20targetedchimericantigenreceptortcellsforrelapsedandrefractorydiffuselargebcelllymphoma